EDEN PRAIRIE, Minn., Feb. 22, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS), today announces it
has expanded its commercial operations team with the addition of three new field clinical specialists to help optimize use of its
Aquadex FlexFlow System within its existing and future customer base. This addition brings the size of the field clinical team to
five.
The field clinical team will enhance sales operations by working with doctors and nurses to optimize the use of the company’s
Aquadex FlexFlow device in patients suffering from fluid overload who have failed diuretic therapy. The company’s clinical
specialists will be based out of New York City, Cleveland, Ohio, Tampa, Fla., Charlotte, N.C. and Chicago, Ill., and will support
the field sales staff nationwide. The company has also hired three field sales representatives for its existing Ohio and Texas
territories and newly created Southeast territory.
“The hiring and deployment of these clinical specialists is an important step in our commercial strategy, as it allows us to
provide clinical instruction and training to existing and new customers alike,” said John Erb, president and CEO of CHF
Solutions. “Ultrafiltration is an important alternative treatment for patients with fluid overload who have failed diuretic
therapy. We are dedicated to educating and supporting doctors and nurses to optimize Aquadex utilization for patients who
need different treatment options. Our clinical specialists will be instrumental in serving this mission.”
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for
Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of
patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of
patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a
healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's
mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical
technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly
owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market
since February 2012.
Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995, including without limitation, the statement regarding the field clinical team enhancing sales operations by working
with doctors and nurses to optimize the use of the company’s FlexFlow device. Forward-looking statements are predictions,
projections and other statements about future events that are based on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking
statements in this release, including, without limitation, those risk associated with our ability to execute on our recently
announced strategic realignment, the possibility that we may be unable to raise sufficient funds necessary for our anticipated
operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with
respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and
uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions
does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com